December 3, 2019
Astellas Pharma has agreed to acquire San Francisco-based Audentes Therapeutics for roughly US$3 billion to move further into the gene therapy arena with the US biotech’s lead program targeting a rare, life-threatening neuromuscular disorder. In the all-cash deal announced on...read more